Status:
COMPLETED
An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Anemia, Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
This observational study will evaluate the clinical benefit of NeoRecormon (epoetin beta) in daily routine practice in cancer patients with anemia. Data will be collected from patients who are receivi...
Eligibility Criteria
Inclusion
- Adult patients, \>/=18 years of age
- Patients receiving myelosuppressive chemotherapy for a solid tumor, a hematological malignancy or an autograft for hematological malignancy
- Patients for whom treatment with epoetin beta is started at the inclusion visit
- Life expectancy \>/=6 months according to the physician
- Patients accepting and able to complete a French written questionnaire about his/her professional and social activities at each visit
Exclusion
- Patients who received erythropoiesis-stimulating agents treatment, or red blood cell transfusion within 4 weeks before enrollment
- Participation in a clinical trial in onco-hematology
- Patients with myelodysplasia
- Patients with more than one active malignancy at the time of enrollment
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
1060 Patients enrolled
Trial Details
Trial ID
NCT01168349
Start Date
January 1 2010
End Date
December 1 2010
Last Update
October 2 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Neuilly-sur-Seine, France, 92521